A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)


Kayikcioglu M., Tokgozoglu L., YILMAZ M., KAYNAR L., Aktan M., Durmus R. B., ...Daha Fazla

ATHEROSCLEROSIS, cilt.270, ss.42-48, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 270
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.atherosclerosis.2018.01.034
  • Dergi Adı: ATHEROSCLEROSIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.42-48
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive intervention to prevent death due to coronary heart disease and/or atherosclerosis. Where available, lipoprotein apheresis (LA) is the mainstay of treatment to promote survival.